- Home
- ERNA vs ATHA Comparison
ERNA vs ATHA Comparison
Compare ERNA & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERNA
- ATHA
- Stock Information
- Founded
- ERNA 2018
- ATHA 2011
- Country
- ERNA United States
- ATHA United States
- Employees
- ERNA N/A
- ATHA N/A
- Industry
- ERNA Biotechnology: Pharmaceutical Preparations
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- ERNA Health Care
- ATHA Health Care
- Exchange
- ERNA Nasdaq
- ATHA Nasdaq
- Market Cap
- ERNA 13.5M
- ATHA 15.7M
- IPO Year
- ERNA N/A
- ATHA 2020
- Fundamental
- Price
- ERNA $1.92
- ATHA $0.45
- Analyst Decision
- ERNA
- ATHA Buy
- Analyst Count
- ERNA 0
- ATHA 4
- Target Price
- ERNA N/A
- ATHA $11.25
- AVG Volume (30 Days)
- ERNA 53.7K
- ATHA 276.4K
- Earning Date
- ERNA 08-12-2025
- ATHA 08-04-2025
- Dividend Yield
- ERNA N/A
- ATHA N/A
- EPS Growth
- ERNA N/A
- ATHA N/A
- EPS
- ERNA N/A
- ATHA N/A
- Revenue
- ERNA $535,000.00
- ATHA N/A
- Revenue This Year
- ERNA N/A
- ATHA N/A
- Revenue Next Year
- ERNA N/A
- ATHA N/A
- P/E Ratio
- ERNA N/A
- ATHA N/A
- Revenue Growth
- ERNA 365.22
- ATHA N/A
- 52 Week Low
- ERNA $1.75
- ATHA $0.22
- 52 Week High
- ERNA $32.40
- ATHA $3.67
- Technical
- Relative Strength Index (RSI)
- ERNA 39.97
- ATHA 63.74
- Support Level
- ERNA $1.91
- ATHA $0.44
- Resistance Level
- ERNA $2.57
- ATHA $0.51
- Average True Range (ATR)
- ERNA 0.18
- ATHA 0.05
- MACD
- ERNA 0.04
- ATHA 0.01
- Stochastic Oscillator
- ERNA 19.77
- ATHA 68.36
About ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.